... A web-based Atlas of Patient-Derived Xenografts of cancer patients:A resource of MURAL PDX data
Home
Search by IDs Search by Gene
Browse
With gene expression Without gene expression Mutation & CNV Plot
Patient Tumor & Clinical details PDX & PDXBiomarker details
View & Update
Statistics



PDX model details

PDX ID 382M
Host Strain(and Source) NSG
Source: Monash University
Host Strain Immune system Humanized NO
Host Type Testosterone supplemented
Graft Site Renal
Current Generation
(* indicates number of generations grown in Castrate host)
 11
Average PDX Generation Time (days +/- SEM) 41 ± 4
Tumor preparation Tumor solid
Tumor Characterization Technology Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq
Tumor confirmed not to be of Mouse/EBV origin Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC
Passage QA performed Routine QA every 2-3 passages
Associated meta data
PDX model availability Yes (fixed, frozen)
Governance restriction for distribution Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements
Pubmed ID 34413304
Markers 382M
AR Y
PSA Y
PSMA Y
NE N
ERG N
This heatmap displays the call type of curated CNVs in the presented samples.
This heatmap displays the call type of CNVs in commonly occurred samples.

PDX ID Gene Symbol CNV Log2 CNV Copy CNV Call Experiments name Platform Reference genome
382M AR -5.06364 0.0299015 homdel MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
382M CDKN1B -0.861204 1.10099 loss MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
382M CHD1 -14.8535 0.0000676 homdel MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
382M CTNNB1 0.643841 3.12497 gain MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
382M FANCA -1.42678 0.74392 loss MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
382M KMT2C 0.537576 2.90306 gain MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
382M KMT2C -0.949299 1.03577 loss MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
382M MYC 1.16424 4.4823 gain MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
382M PIK3CA 0.595957 3.02295 gain MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
382M PIK3CB 0.971282 3.92116 gain MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
382M PTEN -0.96689 1.02322 loss MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
382M RB1 -0.923221 1.05466 loss MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
382M SUFU -0.96689 1.02322 loss MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
382M TP53 -1.40254 0.756525 loss MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19

Clinical Information

Sample Number 382M
Sample Site Liver
Sample source Biopsy
Pathology Tumor Diagnosis None
Gleason Score None
Primary Gleason Score None
Secondary Gleason Score None
Tertiary Gleason Score None
ISUP Grade Group
Tumor Grade
D'Amico Risk Classification
Tumor Volume (in cc) 0.0
Treatment Prior to Specimen Collection ADT, docetaxel, cabazitaxel, abiraterone

Patient Information

Patient Number 175/382
Sex Male
Diagnosis Prostate Cancer
PSA at diagnosis (ng/mL) NA
Consent to share data

Patient Tumor Collection (Current Model)
Tumour sample ID 382M
Patient Age (binned in 5 year age groups) 70-74
This heatmap displays the mutations of curated sequence variants.
Download The Mut plot is not shown
PDX ID Gene Symbol Depth ALT_FREQ Consequence Exon GnomAD_AF CADD_PHRED Clinvar_clnsig Platform Experiments Name Reference Library Type Instrument Type
382M BTK 181 0.99 missense_variant '12/19 . 26.9 - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
382M PTEN 227 0.98 missense_variant '5/9 . 27.2 - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
382M PTCH1 393 0.51 missense_variant '9/24 0.0007269 23.6 Conflicting_interpretations_of_pathogenicity Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
382M SETD2 404 0.48 missense_variant '3/21 0.0005031 29.4 - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
382M LRP2 351 0.47 missense_variant '22/79 . 0.437 - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
382M SPOP 370 0.46 missense_variant '7/12 4.07E-06 23.7 Conflicting_interpretations_of_pathogenicity Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
382M GRIN2A 1018 0.35 missense_variant '13/14 . 24.9 Uncertain_significance Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
382M EPHA5 359 0.32 frameshift_variant '1/18 . . - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
382M MYCN 234 0.31 inframe_deletion '2/3 . . - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
382M AR 381 0.27 inframe_deletion '1/8 . . - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500